SightfileU.S. market data from official filings

10X GENOMICS INC (TXG)

Name: 10X GENOMICS INC (TXG) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001770787 · EDGAR filings · Updated 2026-06-24

10X GENOMICS INC (TXG) has reported institutional ownership of 98.0%, with 329 institutional managers holding positions valued at $2.66B per the latest 13F reporting period.

Institutional ownership

98.0%

Institutional managers

329

Reported 13F value

$2.66B

Insider activity

31 trans.

−$2.64M net selling

Latest updates

2026-06-24 — Insider transaction reported (Form 4)
2026-06-18 — Insider transaction reported (Form 4)
2026-06-16 — Notice of proposed sale filed (Form 144)
2026-06-08 — Insider transaction reported (Form 4)
2026-06-08 — Insider transaction reported (Form 4)
2026-06-08 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, 10X GENOMICS INC has 329 institutional holders and institutional ownership of 98.0%.

Insider activity

Insiders reported 31 transactions (0 buys, 17 sells) across 9 reporting insiders, with a net reported value of −$2.64M.

Related companies

IMMUNOVANT INC (IMVT) · DISC MEDICINE INC (IRON) · HAEMONETICS CORP MASS (HAE) · CATALYST PHARMACEUTICALS INC (CPRX) · BEAM THERAPEUTICS INC (BEAM) · ARCUS BIOSCIENCES INC COM (RCUS)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-24.